Kerendia Starting Dose Recommendation
Start Kerendia 20 mg orally once daily for this patient with eGFR 61 mL/min/1.73 m² and serum potassium 4.0 mmol/L 1.
Dosing Algorithm Based on eGFR and Potassium
The FDA-approved dosing for Kerendia is straightforward and based on two parameters at initiation 1:
Starting Dose Determination:
- eGFR ≥60 mL/min/1.73 m²: Start 20 mg once daily
- eGFR 25-59 mL/min/1.73 m²: Start 10 mg once daily
- eGFR <25 mL/min/1.73 m²: Do not initiate
Potassium Requirements:
- Do not initiate if potassium >5.0 mEq/L 1
- Potassium ≤4.8 mmol/L is ideal for initiation 2, 3
- Potassium 4.9-5.0 mmol/L may be considered with additional monitoring 1
Application to This Patient
Your patient has:
- eGFR 61 mL/min/1.73 m² (≥60 threshold met)
- Potassium 4.0 mmol/L (well below 4.8 mmol/L cutoff)
Both parameters clearly indicate 20 mg once daily as the starting dose 1. This aligns with the most recent KDIGO 2024 guidelines, which specify 20 mg daily for eGFR ≥60 mL/min/1.73 m² when potassium ≤4.8 mmol/L 2.
Post-Initiation Monitoring Protocol
Measure serum potassium at 4 weeks after starting, then adjust dose based on the following algorithm 1:
If on 20 mg daily at 4-week check:
- Potassium ≤4.8 mmol/L: Continue 20 mg daily
- Potassium 4.9-5.5 mmol/L: Continue 20 mg daily (monitor more frequently)
- Potassium >5.5 mmol/L: Withhold drug; restart at 10 mg when potassium ≤5.0 mmol/L
Ongoing Monitoring:
- Check potassium every 4 months during maintenance 2, 3
- More frequent monitoring if patient has risk factors for hyperkalemia (concurrent RAS inhibitors, NSAIDs, potassium-sparing diuretics) 1
Critical Safety Considerations
Common pitfall: Starting at 10 mg when eGFR is just above 60 mL/min/1.73 m². The threshold is clear—eGFR ≥60 requires 20 mg starting dose unless potassium is elevated 1. Your patient's potassium of 4.0 mmol/L provides an excellent safety margin.
Drug interactions to verify: Ensure patient is not on strong CYP3A4 inhibitors (contraindicated) or moderate CYP3A4 inhibitors (requires additional potassium monitoring) 1, 4. Avoid grapefruit juice 1.
eGFR decline: A reversible eGFR decline may occur early after initiation; this is generally not an indication to discontinue unless decline exceeds 30% from baseline 1.
The evidence strongly supports this dosing approach, with the FDA label 1 and KDIGO 2024 guidelines 2 providing identical recommendations. The 2022 ADA/KDIGO consensus 3 established this framework based on the FIDELIO-DKD and FIGARO-DKD trial protocols, which demonstrated significant cardiorenal benefits with this dosing strategy 5.